RNF8–CDH1 Co-Expression Predicts Clinical Benefit of Chemoradiotherapy in Triple-Negative Breast Cancer

RNF8–CDH1 Co-Expression Predicts Clinical Benefit of Chemoradiotherapy in Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is the most aggressive breast cancer subtype and exhibits an overall poor outcome. Due to the lack of targeted therapy, conventional systemic chemotherapy has been the main strategy for the treatment of TNBC. Further evidence has shown that combining radiation wi...

Full description

Bibliographic Details
Main Authors: Chieh-Ni Kao, Sin-Hua Moi, Ming-Feng Hou, Chi-Wen Luo, Fang-Ming Chen, Mei-Ren Pan
Format: Article
Language:English
Published: MDPI AG 2021-07-01
Series:Journal of Personalized Medicine
Subjects:
RNF8
CDH1
TNBC
chemoradiotherapy
Online Access:https://www.mdpi.com/2075-4426/11/7/655

Similar Items

Similar Items